Notice of Intent to Sole Source a Blanket Purchase Agreement (BPA) for a variety of radiopharmaceuticals (radiology medications) for use in the Nuclear Medicine Division at Naval Medical Center San Diego
ID: HT941024N0136Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYFALLS CHURCH, VA, 22042, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/ab197db932f64d57bf684a787aac8f8b/view
Timeline
    Description

    The Department of Defense, through the Defense Health Agency (DHA), intends to award a sole source Blanket Purchase Agreement (BPA) to RLS (USA), Inc. for the procurement of various radiopharmaceuticals required by the Nuclear Medicine Division at Naval Medical Center San Diego (NMCSD). This five-year contract will cover the supply of 31 essential radiopharmaceuticals, four additional medications, and expedited delivery services, all of which are critical for diagnostic imaging and treatment in Nuclear Medicine. Due to the radioactive nature and short shelf-life of these medications, strict adherence to transportation regulations is necessary, with deliveries occurring daily. Interested vendors may submit capability statements by September 10, 2024, to Jennifer Collins at jennifer.e.collins23.civ@health.mil, as this opportunity does not involve competitive proposals.

    Files
    Title
    Posted
    HT941024N0136 NOI.pdf
    The Notice of Intent to Sole Source HT941024N0136 outlines the Defense Health Agency's (DHA) plan to award a five-year Blanket Purchase Agreement (BPA) to RLS (USA), Inc. for the procurement of various radiopharmaceuticals needed at Naval Medical Center San Diego (NMCSD). This sole source award is justified under the Federal Acquisition Regulation's provisions, as RLS is deemed the only provider capable of fulfilling the specific requirements for 31 essential radiopharmaceuticals, four additional medications, and expedited delivery services. Radiopharmaceuticals are crucial for diagnostic imaging and treatments in Nuclear Medicine, warranting strict adherence to transportation regulations due to their radioactive properties and short shelf-life. The BPA is set to be effective from October 1, 2024, to September 30, 2029. Interested parties may submit capability statements by the specified deadline; however, initial competitive proposals are not solicited, as the decision to proceed with a sole source contract rests solely with the government. The document emphasizes the serious nature of the contract and the limited timeframe for vendors to present their qualifications, reflecting standard government RFP practices focused on efficiency and compliance within sensitive health sectors.
    Similar Opportunities
    Q527--Intent to Sole Source Radiopharm Isotopes-Wilkes-Barre VAMC
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, through Network Contracting Office 4, intends to issue a sole source contract for the provision of Radiopharmaceutical Isotopes to the Wilkes-Barre VA Medical Center, specifically with Jubilant Draximage Radiopharmaceuticals Inc. The contract aims to ensure the timely delivery of radiopharmaceuticals that comply with U.S. Nuclear Regulatory Commission (NRC) and Food and Drug Administration (FDA) regulations, thereby prioritizing patient safety and effective healthcare for veterans. This procurement is critical for maintaining high-quality medical services, as the contractor will be required to adhere to strict quality control measures, provide emergency services, and ensure proper packaging and labeling of all materials supplied. Interested vendors must submit a capability statement by September 20, 2024, to the Contracting Specialist, Christa Stine, at christa.stine@va.gov.
    6505--Supply, Axumin-Axumin + Cerianna Medicines - Nuclear Med, CLE
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs intends to solicit and negotiate exclusively with PetNet Solutions and TrillaMed for the supply of three proprietary radiopharmaceuticals—Axumin, Amyvid, and Cerianna—for the Nuclear Medicine Service at the Louis Stokes Cleveland VA Medical Center. These products are critical for diagnosing recurrent prostate cancer, breast cancer, and Alzheimer’s disease, necessitating the use of a local radiopharmacy due to their radioactive nature and short shelf life. Interested vendors may submit their capabilities until September 18, 2024, to determine if a competitive procurement process is feasible, with all inquiries directed to Contract Specialist Don Caldwell at don.caldwell@va.gov.
    Pharmaceutical Preparation Manufacturing
    Active
    Dept Of Defense
    Sources Sought DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking local sources capable and interested in fulfilling a requirement for the procurement and delivery of CLASS VIII, Medical Laboratory Reagents, in support of United States Naval Hospital (USNH), located in Okinawa, Japan. The procurement is for ULTRA TECHNE KOW 18.5GBq Injection Generator, with an estimated quantity of 26 units per year. The delivery location will be the United States Naval Hospital (USNH) Okinawa Nuclear Medicine Department, Camp Foster, Okinawa, Japan. Interested parties should provide company information, capability to provide the items, and item lead times. Responses must be submitted by Thursday, November 09, 2023, via email to jasielle.castro@dla.mil and mamiko.jackson@dla.mil.
    6505--Notice of Intent to Sole Source Pluvicto and Lutathera
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to award a sole source contract to Advanced Accelerator Applications USA for the provision of Pluvicto and Lutathera, specialized radiopharmaceuticals used in the treatment of metastatic castration-resistant prostate cancer and gastroenteropancreatic neuroendocrine tumors. This procurement is justified under FAR regulations due to the unique and highly specialized nature of the therapies required, which limits the availability of suitable suppliers. Interested parties are invited to submit their capability statements, including qualifications and relevant contract information, by 10:00 AM PT on September 25, 2024, to Peter Kim at peter.kim33@va.gov. The contracting office is located in Long Beach, CA, and responses must be submitted electronically; failure to respond may result in the contract being awarded without further solicitation.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for the establishment of Blanket Purchase Agreements (BPA) and Additional Discount Program (ADP) agreements related to pharmaceutical agents under the Defense Health Agency's Uniform Formulary (UF). This procurement aims to secure pricing agreements for various newly approved drugs, including those in the classes of Parkinson's agents, gastrointestinal agents, respiratory agents, hematological agents, targeted immunomodulatory biologics, anticonvulsants, and oncological agents, which will be reviewed during the Pharmacy and Therapeutics (P&T) Committee meeting scheduled for November 6-7, 2024. The initiative is crucial for maintaining an effective pharmacy benefits program for the Military Health System (MHS), ensuring that military personnel have access to high-value medications while adhering to cost-effectiveness criteria. Interested manufacturers must submit their quotes by September 19, 2024, and can direct inquiries to primary contact Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil or secondary contact Tracy Banks at tracy.e.banks2.civ@health.mil.
    6505--Ga68 PSMA Injection (Illucix)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking a contractor to provide Gallium Ga68 (Ga68-PSMA; Illucix®) radiopharmaceutical injections for the VA North Texas Health Care System, with a focus on PET imaging of prostate cancer lesions. The procurement requires contractors to possess a valid license from the US Nuclear Regulatory Commission and adhere to federal and state regulations regarding the handling and transportation of radioactive materials, ensuring safe and efficient delivery of essential medical supplies. Interested parties must submit their quotations by October 8, 2024, at 3:00 PM CST, to the designated Contract Specialist, Vance Farrell, via email, with the anticipated delivery period set from October 25, 2024, to October 24, 2025.
    Maintenance for fMRI software
    Active
    Dept Of Defense
    The Defense Health Agency (DHA) intends to award a sole source contract to Nordic Neuro Lab, Inc. for maintenance services related to the existing NordicBrain software and hardware at Walter Reed National Military Medical Center (WRNMMC) in Bethesda, Maryland. This procurement aims to ensure ongoing support and maintenance of specialized medical software and hardware that are critical for the operations of the Radiology Department at WRNMMC. The contract will be awarded under the authority permitting Other than Full and Open Competition, with interested parties required to express their capabilities by 10:00 AM EST on September 19, 2024, via email to the primary contact, Ealed Nuru, at ealed.m.nuru.civ@health.mil, with a copy to Erica S. Oh at erica.s.oh.civ@health.mil.
    Lab Radiological Sample Analysis Contract
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting proposals for a Lab Radiological Sample Analysis Contract to support the Defense Centers for Public Health - Aberdeen (DCPH-A). This contract involves the non-personal services requirement for the analysis of radiological samples across various parameters, which is crucial for enhancing public health readiness and ensuring the quality of the Public Health Enterprise. The solicitation is prepared in accordance with Federal Acquisition Regulation (FAR) guidelines, and interested vendors are required to submit quotes as no written solicitation will be issued. For further details, interested parties can contact Kenneth Grenier at kenneth.e.grenier2.civ@health.mil or by phone at 301-619-2728, with the archive date for submissions set for October 4, 2024.
    BPA - X-RAY FILM AND SUPPLIES PSC 6525
    Active
    Dept Of Defense
    The Department of Defense, specifically the Department of the Navy's Naval Surface Warfare Center Indian Head Division, has issued a Combined Synopsis/Solicitation notice for the procurement of X-ray film and supplies. These supplies are typically used in medical, dental, and veterinary imaging equipment. The procurement will be a Total Small Business Set-Aside and the place of performance is Indian Head, Maryland. The notice includes a list of specific items that will be procured, such as radiographic film and radiographic processing chemicals. Interested companies must provide documentation addressing their capabilities and expertise, as well as a price list if applicable. Blanket Purchase Agreements (BPAs) will be awarded based on positive Past Performance, and interested vendors should provide a minimum of three Past Performance References. The government reserves the right to use additional references if available. Vendors should also have an active account in the Procurement Integrated Enterprise Environment (PIEE) and the System for Award Management (SAM). The government intends to issue Master BPAs on a 6-month rotation through February 2029. Interested vendors should submit documentation and references by email to Barbara.j.grinder.civ@us.navy.mil. The Points of Contact for this procurement are Barbara Grinder and Brandi Sorzano.
    Medical Reagents for USNH Okinawa
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) Troop Support Pacific is conducting a sources sought announcement to identify local sources capable of providing medical laboratory reagents for the United States Naval Hospital (USNH) in Okinawa, Japan. The procurement involves the delivery of CLASS VIII medical laboratory reagents, including Ortho reagents and consumables compatible with VITROS 5600 Analyzers, along with necessary training and maintenance services for the equipment. This opportunity is critical for ensuring the availability of essential medical supplies and maintaining compliance with healthcare standards in a military setting. Interested parties must submit their qualifications and relevant information by September 30, 2024, to the primary contacts, Bradley Ah Nee and Arlene Renner, via email at bradley.ahnee@dla.mil and arlene.renner@dla.mil, respectively. The estimated contract value is under $5.4 million, covering a base period of 12 months with two optional periods.